Vergelijking

Ganirelix vs. Octreotide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

123246-29-7

83150-76-9

Molecuulmassa

1570.3 g/mol

1019.24 g/mol

Halfwaardetijd

geen gegevens

1.7 h

Sequentie

geen gegevens

D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)

Werkingsmechanisme

Ganirelix

Ganirelix competitively and reversibly binds the pituitary GnRH receptor, rapidly suppressing LH (and, less so, FSH) release — without the initial hormone 'flare' of GnRH agonists.

Octreotide

Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Ganirelix	Octreotide
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Ganirelix

Volledige vermelding →

Octreotide

Volledige vermelding →

Frequently asked questions

What is the difference between Ganirelix and Octreotide?: Ganirelix is classified as "Onderzoek (overig)", while Octreotide is classified as "Onderzoek (overig)". Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Ganirelix or Octreotide?: The highest available evidence level is "Humane RCT" for Ganirelix and "Humane RCT" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Ganirelix and Octreotide in Germany and the United States?: Duitsland: Ganirelix — Op recept, Octreotide — Op recept. Verenigde Staten: Ganirelix — Op recept, Octreotide — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Ganirelix

Octreotide

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Ganirelix and Octreotide?

Ganirelix is classified as "Onderzoek (overig)", while Octreotide is classified as "Onderzoek (overig)". Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Ganirelix or Octreotide?

The highest available evidence level is "Humane RCT" for Ganirelix and "Humane RCT" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Ganirelix and Octreotide in Germany and the United States?

Duitsland: Ganirelix — Op recept, Octreotide — Op recept. Verenigde Staten: Ganirelix — Op recept, Octreotide — Op recept. These are factual summaries with source and review date on the individual pages.